3.79 0.23 (6.46%) | 04-26 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 4.73 | 1-year : | 5.52 |
Resists | First : | 4.05 | Second : | 4.73 |
Pivot price | 3.59 | |||
Supports | First : | 3.43 | Second : | 3.04 |
MAs | MA(5) : | 3.63 | MA(20) : | 3.49 |
MA(100) : | 2.46 | MA(250) : | 2.53 | |
MACD | MACD : | 0.2 | Signal : | 0.2 |
%K %D | K(14,3) : | 54 | D(3) : | 51.2 |
RSI | RSI(14): 64.2 | |||
52-week | High : | 4.05 | Low : | 1.63 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GERN ] has closed below upper band by 13.8%. Bollinger Bands are 23.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 3.6 - 3.62 | 3.62 - 3.64 |
Low: | 3.31 - 3.34 | 3.34 - 3.35 |
Close: | 3.53 - 3.56 | 3.56 - 3.59 |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Thu, 25 Apr 2024
Geron to Announce First Quarter 2024 Financial Results on May 2, 2024 - Business Wire
Tue, 23 Apr 2024
With 55% ownership in Geron Corporation (NASDAQ:GERN), institutional investors have a lot riding on the business - Simply Wall St
Thu, 11 Apr 2024
Considering The Merits Of A Gamble On Geron Corporation (NASDAQ:GERN) - Seeking Alpha
Thu, 11 Apr 2024
Geron Corporation (NASDAQ:GERN) Is Expected To Breakeven In The Near Future - Yahoo Finance
Fri, 15 Mar 2024
Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up - Zacks Investment Research
Fri, 15 Mar 2024
Geron’s stock soars 95% after FDA panel votes in favor of blood-disorder drug - MarketWatch
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 589 (M) |
Held by Insiders | 4.7507e+008 (%) |
Held by Institutions | 0 (%) |
Shares Short | 44,910 (K) |
Shares Short P.Month | 0 (K) |
EPS | -1.935e+008 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -236 % |
Return on Assets (ttm) | 39.1 % |
Return on Equity (ttm) | -41.5 % |
Qtrly Rev. Growth | 237000 % |
Gross Profit (p.s.) | -127.38 |
Sales Per Share | -184.09 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -0.4 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -168 (M) |
PE Ratio | -0.01 |
PEG Ratio | -2.3 |
Price to Book value | 0 |
Price to Sales | -0.03 |
Price to Cash Flow | 5.02 |
Dividend | 0 |
Forward Dividend | 4.666e+007 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |